ENDRA Life Sciences Inc.
NDRA Nasdaq
SEC CIK 1681682
Follow ENDRA Life Sciences
Weekly email: filings, results
Net income
−$1.5M
+4.2% vs same quarter last year
EPS, diluted
−$1.02
+51.4% vs same quarter last year
Operating cash flow
−$1.8M
−50.6% vs same quarter last year
Operating income
−$1.7M
−25.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$7M |
| FY24 | - | −$11.5M |
| FY23 | - | −$10.1M |
| FY22 | - | −$13.2M |
| FY21 | - | −$11.2M |
| FY20 | $0 | −$11.7M |
| FY19 | $0 | −$13.3M |
| FY18 | $6.2K | −$9.8M |
| FY17 | $351.6K | −$5.4M |
| FY16 | $515.6K | −$2.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | 100% | −146080.5% | −158669.6% |
| FY17 | 50.9% | −1315.6% | −1529.2% |
| FY16 | 54.3% | −347.5% | −538.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$5.2M |
| FY24 | −$7.4M |
| FY23 | −$9.6M |
| FY22 | −$13M |
| FY21 | −$11.2M |
| FY20 | −$10.8M |
| FY19 | −$8.6M |
| FY18 | −$7.8M |
| FY17 | −$3.3M |
| FY16 | - |
- ENDRA Life Sciences
- Healthcare median
Show the numbers
| Year | ENDRA Life Sciences | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | −158669.6% | −49.6% |
| FY17 | −1529.2% | −45.9% |
| FY16 | −538.3% | −36% |